US 7,612,095 B2
Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid
Aurelio Orjales Venero, Neguri (Spain); Maravillas Bordell Martin, Leioa (Spain); Gonzalo Canal Mori, Leioa (Spain); Haydee Blanco Fuente, Las Arenas (Spain); Maria Luisa Lucero De Pablo, Algorta (Spain); Victor Rubio Royo, Getxo (Spain); and Ramon Mosquera Pestaña, Las Arenas (Spain)
Assigned to Faes Farma, S.A., (Spain)
Appl. No. 10/511,822
PCT Filed Apr. 19, 2002, PCT No. PCT/ES02/00194
§ 371(c)(1), (2), (4) Date Mar. 23, 2005,
PCT Pub. No. WO03/089425, PCT Pub. Date Oct. 30, 2003.
Prior Publication US 2005/0203141 A1, Sep. 15, 2005
Int. Cl. A61K 31/454 (2006.01); C07D 43/04 (2006.01)
U.S. Cl. 514—322  [546/199] 6 Claims
 
1. A crystalline form 1 of bilastine having, upon X-ray crystallography analysis, crystal parameters of substantially the following:
   
  Crystallographic system Monoclinic  
  Spatial group P2 (1)/c
  Crystal size 0.56 × 0.45 × 0.24 mm
  Cell dimension a = 23.38 (5) A angstrom α = 90°
    b = 8.829 (17) A β = 90°
    c = 12.59 (2) A Y = 90°
  Volume 2600 A3
  Z, calculated density 4, 1.184 mg/m3,
   
an infrared spectrum in potassium bromide with the following bands:
Wavenumber (cm−1)
3057
2929
2883
2857
2797
1666
1481
1431
1346
1326
1288
1020
973
945
829
and an infrared spectrum in potassium bromide which is substantially identical to that shown in FIG. 1.